Dapagliflozin 10mg + Sitagliptin 50mg Tablets

Dapagliflozin + Sitagliptin combines two glucose-lowering medicines for adults with type 2 diabetes. It brings together complementary approaches when a single medicine does not provide adequate blood glucose control alongside diet and activity.
Swallow the tablet with water at a consistent daily time, with or without food. Maintain normal fluid intake. A planned fast, operation or illness causing poor food and fluid intake may require a temporary treatment change.
Dapagliflozin blocks kidney SGLT2 transporters to increase glucose excretion in urine. Sitagliptin inhibits DPP-4, prolonging incretin activity to support glucose-dependent insulin release and reduce glucagon.
Genital fungal infection, increased urination, thirst, dizziness and headache can occur. Persistent severe abdominal pain, repeated vomiting or difficult breathing may indicate pancreatitis or ketoacidosis. Severe genital pain or swelling also needs urgent assessment.
Kidney function affects use of both components. Tell your doctor about pancreatitis, dehydration, recurrent genital infection and insulin or sulfonylurea treatment. It is not a treatment for type 1 diabetes or diabetic ketoacidosis. Ketoacidosis can occur without very high glucose, while insulin or sulfonylureas can add hypoglycaemia risk.
Combines kidney-based glucose excretion with incretin-dependent glucose control. The intrinsic risk of hypoglycaemia is low unless it is combined with insulin or a sulfonylurea.
No. Glucose in the urine is an expected effect of dapagliflozin and does not by itself show poor control.
The risk is higher when it is combined with insulin or a sulfonylurea, even though the combination alone has a relatively low intrinsic risk.
Persistent severe upper-abdominal pain, sometimes spreading to the back and accompanied by vomiting, needs urgent assessment.
Dapagliflozin increases glucose in the urine, which can encourage genital fungal infection. Persistent itching, redness or discharge needs assessment and appropriate treatment.
SGLT2: a kidney glucose transporter. DPP-4: an enzyme that breaks down incretin hormones. Incretin: a gut hormone influencing insulin and glucagon. Pancreatitis: inflammation of the pancreas.; AR: Dapagliflozin 10mg + Sitagliptin 50mg أقراص; FR: Dapagliflozin 10mg + Sitagliptin 50mg comprimés; PT: Dapagliflozin 10mg + Sitagliptin 50mg comprimidos; ES: Dapagliflozin 10mg + Sitagliptin 50mg comprimidos; RU: Dapagliflozin 10mg + Sitagliptin 50mg таблетки; ID: Dapagliflozin 10mg + Sitagliptin 50mg tablet; VI: Dapagliflozin 10mg + Sitagliptin 50mg viên nén; MS: Dapagliflozin 10mg + Sitagliptin 50mg tablet; TL: Dapagliflozin 10mg + Sitagliptin 50mg mga tableta; ZH-SG: Dapagliflozin 10mg + Sitagliptin 50mg 片剂
International B2B Enquiry
Send a structured B2B enquiry for Dapagliflozin 10mg + Sitagliptin 50mg Tablets under Diabetes Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Dapagliflozin 10mg + Sitagliptin 50mg Tablets